Skip to content

Prospective Registry-Based Study of Endovascular Treatment for Symptomatic Carotid Artery Dissection in China

Prospective Registry-Based Study of Endovascular Treatment for Symptomatic Carotid Artery Dissection in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116982
Enrollment
Unknown
Registered
2026-01-18
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke, symptomatic carotid dissection

Interventions

exposure group:EVT+SMT
control group:SMT

Sponsors

The Second Affiliated Hospital of the Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 18 =<age =<100; 1.The first onset was diagnosed as acute CAD by imaging examination. The symptoms included ischemic stroke or TIA confirmed by brain computed tomography (CT) or magnetic resonance imaging (MRI), headache confirmed by VAS, neck pain, Horner syndrome and neurological deficit confirmed by NIHSS score. 2.Written informed consent signed by patients or family members;

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women; 2.mRS score>= 2 before onset; 3.Cardiogenic stroke or potential cardiogenic thrombosis, with any of the following clear causes of cardiogenic embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardial thrombus or implant, dilated cardiomyopathy, left atrial autoacoustic imaging; 4.Blood glucose22.2mmol/l, platelet3; 8.Expected failure to complete follow-up; 9.Brain hernia leads to midline displacement of brain; 10.Intracranial aneurysms, arteriovenous malformations; 11.Intracranial space occupying lesions; 12.Life expectancy185mmhg or diastolic blood pressure>110mmhg, and antihypertensive drugs can not be controlled; 14.Carotid artery dissection caused by iatrogenic or traumatic trauma.

Design outcomes

Primary

MeasureTime frame
mRS score distribution at 90 days;24h symptomatic cerebral hemorrhage (Sich);90 day mortality;

Secondary

MeasureTime frame
mRS score 0-1 at 90 days (%);mRS score 0-3 at 90 days (%);Modified thrombolytic therapy for cerebral infarction (mtici) score;Changes of NIHSS score 24 hours after treatment;90 day EQ-5D scale score;mRS score 0-4 at 90 days (%);Changes of NIHSS score 48 hours after treatment;NIHSS score changes 5-7 days after treatment; If the time of discharge is earlier than 5-7 days, the time of discharge shall prevail;mRS score 0-2 at 90 days (%);mRS changes from baseline to 90 days (?mRS a sequential scale from -2, -1, 0, 1, 2, 3, 4, 5, 6);

Countries

China

Contacts

Public ContactWenjie Zi

The Second Affiliated Hospital of the Army Medical University

ziwenjie@126.com+86 185 2303 3816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026